Thymosin Alpha-1

Scientific identity: Thymosin Alpha-1 is a 28-amino-acid acetylated peptide derived from the N-terminal sequence of prothymosin alpha. The peptide carries an N-terminal acetyl group — a post-translational modification present in the endogenous form — which contributes to its stability and biological activity in experimental systems. Its sequence is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH.

Peptide class: Synthetic thymic peptide; immunomodulatory peptide; N-terminally acetylated acidic peptide derived from prothymosin alpha.

Primary research targets: Toll-like receptor 2 (TLR2) and toll-like receptor 9 (TLR9) — pattern recognition receptors involved in innate immune activation — along with downstream signaling in dendritic cells, T-helper cell differentiation, and regulatory T-cell biology.

Research areas: Immunomodulatory peptide research, T-cell biology, innate immune signaling, TLR pathway pharmacology, dendritic cell activation research, thymic biology, antiviral immune response models, tumor immunology research.

Product quantity: 10mg per vial.

Purity: Greater than 99%, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering compound identity, purity, and lot traceability.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans outside of regulated research settings.

TLR Pathway and Innate Immune Signaling

Research has proposed that Thymosin Alpha-1 engages toll-like receptors — particularly TLR2 and TLR9 — expressed on dendritic cells and macrophages, activating downstream innate immune signaling cascades including NF-κB and MyD88-dependent pathways. These receptor interactions have been characterised in cell-based systems and animal models. Published work has examined Tα1-associated changes in cytokine profiles — including IL-12, IFN-γ, and IL-10 — in defined experimental immune models. These findings represent preclinical observations in specific cell and animal systems.

T-Cell Biology Research

Thymosin Alpha-1 has been studied in the context of T-cell maturation, differentiation, and function. Research has examined its proposed role in promoting T-helper 1 (Th1) polarisation and supporting regulatory T-cell (Treg) activity in experimental immune models. Cell-based studies have measured T-cell proliferation, cytokine secretion, and surface marker expression following Tα1 exposure under defined experimental conditions. These findings are model-specific and reflect research into thymic peptide biology rather than established therapeutic mechanisms.

Human Clinical Research

Thymosin Alpha-1 has an unusually extensive human clinical literature for a research peptide. Studies have investigated Tα1 (as Zadaxin) in contexts including chronic hepatitis B and C, certain oncology settings, and immune reconstitution research in immunocompromised populations. Regulatory approvals for Zadaxin exist in a number of jurisdictions for specific indications. These approvals concern regulated pharmaceutical-grade formulations under defined clinical conditions and do not establish the safety, efficacy, pharmacokinetic equivalence, or bioavailability of the Longevia Research research vial.

Research Status

Thymosin Alpha-1 has one of the most developed clinical and preclinical research profiles of any immunomodulatory peptide. Pharmaceutical Zadaxin holds regulatory approval in certain jurisdictions for specific indications. As a research tool, synthetic Tα1 remains actively used in immunology, virology, and oncology research models. The Longevia Research vial is supplied for Research Use Only with no clinical or pharmaceutical designation.

Reliable research begins with accurately characterised material. For a 28-amino-acid acetylated peptide such as Thymosin Alpha-1, that means confirming sequence integrity, N-terminal acetylation, and purity at the batch level — because loss of the N-terminal acetyl group produces a structurally distinct peptide with a different biological activity profile in immunological assay systems.

Purity assessment: Each production lot is characterised to greater than 99% purity by high-performance liquid chromatography (HPLC). Chromatographic purity data is reported on the batch Certificate of Analysis.

Identity confirmation: Peptide identity and N-terminal acetylation are confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the acetylated form. HPLC and LC-MS data together confirm that the material supplied corresponds to the labelled compound at the labelled purity.

Batch traceability and Certificate of Analysis: Every vial of Thymosin Alpha-1 10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information. Researchers evaluating this material for assay work are encouraged to review the current batch documentation before use, since analytical specifications are applied at the lot level.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade immunomodulatory peptides.

Longevia Research supplies Thymosin Alpha-1 10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Thymosin Alpha-1 is a synthetic research peptide supplied strictly as a research tool. It is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. While pharmaceutical Thymosin Alpha-1 formulations hold regulatory approval for specific indications in certain jurisdictions, no such approval applies to this Longevia Research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this compound. The scientific literature summarised on this product page describes experimental observations in defined cell-based, animal, and human research systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.